Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Zen Graphene Solutions Ltd. (TSXV: ZEN) (OTC Pink: ZENYF) ("ZEN" or the "Company") is pleased to announce the following related to its proprietary, graphene-based coating that is 99.9% effective against aerobic bacteria (gram-positive and gram-negative), fungi and viruses, including COVID-19:

• On January 16^th, 2021, ZEN reached an agreement with TreborRx (Trebor) for application of its coating on nitrile gloves sourced or produced by Trebor
• ZEN will provide Trebor with a distribution agreement for Canada, the USA and Mexico (Territory)
• Trebor agrees to use the coating on all gloves sold and will pay ZEN a royalty per glove coated, with a minimum first year guarantee of 100 million gloves
• Trebor surgical masks without our coating have received Health Canada (HC) approval as a level 1 medical device in line with American Society for Testing and Materials (ASTM) standards, and expect HC approval for level 2 and 3 shortly

Greg Fenton, ZEN CEO, commented, "We are very excited to build upon our initial partnership agreement with the team at TreborRx by extending the benefits of our coating to the nitrile glove market. This is a tremendous opportunity for both our companies and demonstrates the strength of our relationship and mutual pursuit of creating value and protecting our front-line workers. Additionally, we are pleased that both companies continue to make progress toward getting Health Canada approval and bringing PPE treated with our biocidal coating to market."

Zen Graphene Solutions Ltd. (TSXV: ZEN) (OTC Pink: ZENYF) ("ZEN" or the "Company") is pleased to announce the following related to its proprietary, graphene-based coating that is 99.9% effective against aerobic bacteria (gram-positive and gram-negative), fungal and viral activity, including COVID-19:

• Confirmation from a major Canadian Certification company that filter material flow rates and pressure drop were not affected by the application of the coating
• Confirmation from The BIG-nano Corporation (BIG-nano) that treated mask material achieved excellent dispersion and coverage, and the coating did not block fiber pores
• Both findings help validate that ZEN's coating does not inhibit breathability in polypropylene mask material or flow rates in air filtration media

Greg Fenton, ZEN CEO, commented: "Demonstrating that the application of our coating on both filtration and mask materials does not negatively affect the air flow or breathability is another meaningful step towards realizing the full potential of our novel graphene-based solutions. We believe the personal protective equipment (PPE) and air filtration markets have enormous potential for our company as we develop vital tools in our collective fight against pathogens, like SARS-CoV-2."

Zen Graphene Solutions Ltd. (TSXV: ZEN) (OTC Pink: ZENYF) ("ZEN" or the "Company") announces stock option grants for its directors, officers, employees and consultants. These options are exercisable for an aggregate of 1,425,000 common shares at an exercise price of $3.32 per common share for a period of three to five years from the date of the grant. Directors and officers of the company were granted 1,300,000 options which will vest one-third on the date of grant, one-third after six months of the date of grant and one-third after 12 months of the date of grant. The remaining 125,000 options issued to employees and consultants will vest as to one-third on the date of grant, one-third on the first anniversary of the date of grant and one-third on the second anniversary of the date of grant.

Zen Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV: ZEN) (OTC: ZENYF) is pleased to announce the following:

• Preliminary cytotoxicity results of its graphene-based antibiotic, antiviral and antifungal compound show no apparent negative impacts in animals dosed with a concentration many thousands of times higher than that found to be effective in testing recently completed at Mount Sinai hospital. Phase 2 testing results expected in late-January
• At 108 days, testing results of polypropylene mask material treated with ZEN's coating demonstrated 98% effectivity against COVID-19
• ZEN's Graphene-based coating achieved greater than 99% efficacy against both gram-positive and gram-negative bacteria at McMaster University
• A new test program at Mount Sinai with Dr. Tony Mazzulli will focus on the efficacy of ZEN's graphene-based compound on multi-drug resistant organisms

Greg Fenton, ZEN CEO, commented: "We continue to receive extremely encouraging results related to our graphene-based biocidal solutions. The most significant of these being that preliminary cytotoxicity results for ZEN's potential antibiotic, antiviral, and antifungal compound suggest that it could be a potential medical breakthrough treatment for human-contracted pathogens. Additionally, the most recent results confirm that our graphene-based coating applied to mask material remains highly effective against COVID-19 after more than three months. Consistent with our recently announced graphene-based compound for treating human-contracted pathogens, we have also confirmed that it is greater than 99% effective against gram-positive and gram-negative bacteria. This demonstrates that our coating on masks and other personal protective equipment has potential broad biocidal properties and applications that we believe will go far beyond protection against COVID-19."

Zen Graphene Solutions Ltd. (TSXV: ZEN) (OTC Pink: ZENYF) ("ZEN" or the "Company") is pleased to announce that it has developed a potential graphene-based antibiotic, antiviral and antifungal compound. Recently received testing results from the University Health NetworkMount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens including, upper and lower respiratory tract infections - where COVID-19 is a major contributor - as well as drug resistant organisms. Testing was conducted by Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief & Infectious Disease Specialist at Mount Sinai Hospital. Dr. Mazzulli is also a Professor at the Departments of Laboratory Medicine & Pathobiology and Medicine at the University of Toronto.